New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback